Skip to main navigation

Contact Us
Join Us
LinkedIn

Our Company
Our Areas of Focus
- Ophthalmology
  - Diabetic Macular Edema I OCS-01
  - Dry Eye Disease I Licaminlimab
- Neuro-Ophthalmology
  - Optic Neuritis I Privosegtor
  - NAION I Privosegtor
Our Innovation
Investors and Media
- Column
- Column

Our Company
Our Areas of Focus
- Ophthalmology
  - Diabetic Macular Edema I OCS-01 Diabetic Macular Edema I OCS-01
  - Dry Eye Disease I Licaminlimab Dry Eye Disease I Licaminlimab
- Neuro-Ophthalmology
  - Optic Neuritis I Privosegtor Post-Ocular Surgery
  - NAION I Privosegtor Dry Eye Disease
Our Innovation
Investors and Media
- Column
- Column

Public Disclosures

Overview
Stock
Releases
In the News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

Overview
Stock
Releases
In the News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

Public Disclosures

Mar 05, 2026

2025 Financial Results

2025 Consolidated IFRS Financial Statements 1 MB

2025 MD&A 309.2 KB

ESEF reporting 2.8 MB

Nov 10, 2025

Q3 2025 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2025 364.2 KB

Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2025 284.4 KB

Aug 21, 2025

Q2 2025 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Six Months Ended June 30, 2025 239.5 KB

Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2025 242.9 KB

May 08, 2025

Q1 2025 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2025 270.2 KB

Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2025 212.9 KB

Mar 11, 2025

2024 Financial Results

2024 Consolidated IFRS Financial Statements 535.7 KB

2024 MD&A 232.6 KB

ESEF reporting 1.4 MB

Nov 07, 2024

Q3 2024 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Nine Months Ended September 30, 2024 329.6 KB

Management Discussion and Analysis of Financial Condition and Results of Operations for the Nine Months Ended September 30, 2024 261.1 KB

Aug 27, 2024

Q2 2024 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Six Months Ended June 30, 2024 298.8 KB

Management Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2024 262.4 KB

May 08, 2024

Q1 2024 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2024 228.2 KB

Management Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2024 207.1 KB

Apr 22, 2024

Supplement to Prospectus Nasdaq Iceland Main Market Listing

Oculis Supplement to Prospectus Nasdaq Iceland Main Market Listing 802.1 KB

Apr 11, 2024

Prospectus Nasdaq Iceland Main Market Listing

Oculis Prospectus Nasdaq Iceland Main Market Listing 2.1 MB

Visionary Innovation

Our Company
About Us
Governance
Our Culture
Contact Us
Join Us
LinkedIn

Our Areas of Focus
Ophthalmology
Diabetic Macular Edema I OCS-01
Dry Eye Disease I Licaminlimab
Neuro-Ophthalmology
Optic Neuritis I Privosegtor
NAION I Privosegtor

Our Innovation
Pipeline
Clinical Trials
Expanded Access Policy
Science
Publications

Investors and Media
Overview
Stock Information
News Releases
In the News
Events & Presentations
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources

© 2026 Oculis All Rights Reserved

Terms of Use
Privacy Notice
Cookie Policy
Expanded Access Policy